Treatment of glaucoma and ocular hypertension

• US 6,177,427 B1
• Filed: 07/01/1999
• Issued: 01/23/2001
• Est. Priority Date: 06/28/1994
• Status: Expired due to Fees

• Current Assignee: Alcon Research Limited (Nestle SA)
• Original Assignee: Alcon Laboratories Incorporated (Alcon Incorporated)
• Inventors: Conrow, Raymond E., Clark, Abbot F.
• Primary Examiner(s): BADIO, BARBARA P
• Application Number:
  US09/346,424
• Time in Patent Office: 572 Days
• Field of Search: 514/396, 514/397, 514/239.2, 514/255, 514/406, 514/383, 548/346.1, 548/314.7, 548/262.2, 548/572, 548/373.1, 544/177, 544/396
• US Class Current: 514/239.2
• CPC Class Codes: C07D 207/08 with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
• CPC Class Codes: C07D 213/36 Radicals substituted by singly-bound nitrogen atoms nitro radicals C07D213/26
• CPC Class Codes: C07D 231/12 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 233/62 with triarylmethyl radicals attached to ring nitrogen atoms
• CPC Class Codes: C07D 249/08 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• CPC Class Codes: C07D 249/12 Oxygen or sulfur atoms
• CPC Class Codes: C07D 295/088 to an acyclic saturated chain
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 405/06 linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compositions of non-steroidal glucocorticoid antagonists for treating glaucoma or ocular hypertension and methods for their use are disclosed.

Claims

1. A compound selected from the group consisting of:

N-(2-[4,4′

,4″

-Trichlorotrityl]oxyethyl)morpholine;

1-(2[4,4′

,4″

-Trichlorotrityl]oxyethyl)-4-(2-hydroxyethyl)piperazine dimaleate;

9-(3-Mercapto-1,2,4-trazolyl)-9-phenyl-2,7-difluorofluorenone;

1-(2-Chlorotrityl)-3,5-dimethylpyrazole;

N-(2-Chlorotrityl)-L-prolinol acetate;

1, S-Bis(4,4′

,4″

-trichlorotrityl)-1,2,4-triazole-3-thiol.

2. A method for treating glaucoma or ocular hypertension by administering a pharmaceutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

3. A composition for controlling glaucoma or ocular hypertension comprising a pharmaceutically effective amount a compound of claim 1.